Mylatabi (Eltrombopag)

Eltrombopag, the active ingredient in Mylatabi, is a thrombopoietin receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C in appropriate patient populations.

GNH USA supplies Mylatabi as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Eltrombopag is used to stimulate platelet production in disorders characterized by thrombocytopenia.

- Chronic immune thrombocytopenia (ITP): increases platelet counts to reduce bleeding risk. - Severe aplastic anemia: supports hematopoiesis by raising platelet levels in patients refractory to other treatments. - Thrombocytopenia associated with chronic hepatitis C: improves platelet counts to facilitate antiviral therapy.

Eltrombopag may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Headache - Elevated liver enzymes - Dyspepsia

Serious or Rare Side Effects: - Hepatic failure - Severe thrombotic events - Neutropenia - Anaphylactic reactions - Retinal pigment epithelium changes

When prescribing or dispensing Eltrombopag, several safety considerations should be observed.

- Liver function monitoring: check hepatic enzymes regularly. - Thrombotic risk assessment: avoid in patients with active thrombosis. - Hypertension control: use caution in uncontrolled high blood pressure. - Pregnancy and lactation: risk unknown, weigh benefits against potential hazards. - Discontinue if severe adverse reactions occur. - Store at room temperature: keep in the original pack, protect from moisture.

Eltrombopag can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce drug exposure. - Antacids containing polyvalent cations: impair absorption. - Concurrent use with other thrombopoietin receptor agonists: risk of excessive platelet rise.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may increase plasma levels. - Warfarin: potential alteration of INR, requiring closer monitoring.